Research and Markets: Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insights 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3fx8p2/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Insights, 2014" subscription to their offering.

This Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Non Alcoholic Fatty Liver Disease (NAFLD).

This report provides information on the therapeutic development based on the Non Alcoholic Fatty Liver Disease (NAFLD) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Non Alcoholic Fatty Liver Disease (NAFLD) Overview
  2. Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics
  3. Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Development by Companies
  4. Non Alcoholic Fatty Liver Disease (NAFLD) Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Non Alcoholic Fatty Liver Disease (NAFLD) Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Non Alcoholic Fatty Liver Disease (NAFLD) Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Non Alcoholic Fatty Liver Disease (NAFLD) Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
  19. Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Products
  20. Companies Involved in Therapeutics Development for Non Alcoholic Fatty Liver Disease (NAFLD)
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/3fx8p2/non_alcoholic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals